Perspectives on the HIV continuum of care among adult opioid users in New York City: a qualitative study

Harm Reduction Journal - Tập 16 Số 1 - 2019
Babak Tofighi1, Selena S. Sindhu1, Chemi Chemi1, Crystal Fuller Lewis2, Victoria Vaughan Dickson3, Joshua D. Lee4
1Department of Population Health, New York University School of Medicine, 180 Madison Avenue, New York, NY, 10016, USA
2Department of Psychiatry, New York University School of Medicine, New York, USA
3NYU Meyers College of Nursing, New York, USA
4Division of General Internal Medicine and Clinical Innovation, New York University School of Medicine, 180 Madison Avenue, New York, NY, 10016, USA

Tóm tắt

Abstract Background Engagement in the HIV care continuum combined with office-based opioid treatment remains a cornerstone in addressing the intertwined epidemics of opioid use disorder (OUD) and HIV/AIDS. Factors influencing patient engagement with OUD and HIV care are complex and require further study. Methods In this qualitative study, in-depth interviews were conducted among 23 adult patients who use drugs (PWUD) in an inpatient detoxification program in New York City. The semi-structured interview guide elicited participant experiences with various phases of the HIV care continuum, including factors influencing access to HIV care, interactions with HIV and primary care providers, preferences around integrated care approaches for OUD and HIV, and barriers experienced beyond clinical settings which affected access to HIV care (e.g., insurance issues, transportation, cost, retrieving prescriptions from their pharmacy). Data collection and thematic analysis took place concurrently using an iterative process-based established qualitative research method. Results Respondents elicited high acceptability for integrated or co-located care for HIV and OUD in primary care. Factors influencing engagement in HIV care included (1) access to rapid point-of-care HIV testing and counseling services, (2) insurance coverage and costs related to HIV testing and receipt of antiretroviral therapy (ART), (3) primary care providers offering HIV care and buprenorphine, (4) illicit ART sales to pharmacies, (5) disruption in supplies of ART following admissions to inpatient detoxification or residential treatment programs, (6) in-person and telephone contact with peer support networks and clinic staff, (7) stigma, and (8) access to administrative support in primary care to facilitate reengagement with care following relapse, behavioral health services, transportation vouchers, and relocation from subsidized housing exposing patients to actively using peers. Conclusion These findings suggest expanding clinical and administrative support in primary care for PWUDs with patient navigators, case managers, mobile health interventions, and peer support networks to promote linkage and retention in care.

Từ khóa


Tài liệu tham khảo

Sidibé M, Loures L, Samb B. The UNAIDS 90–90–90 target: a clear choice for ending AIDS and for sustainable health and development. J Int AIDS Soc. 2016;19(1):21133.

Turner A, Harripersaud K, Crawford N, Rivera A, Fuller C. Differences in HIV risk behavior of injection drug users in New York City by health care setting. AIDS Care. 2013;25(10):1321–9.

Des Jarlais DC, McKnight C, Feelemyer J, et al. Heterosexual male and female disparities in HIV infection at the end of an epidemic: HIV infection among persons who inject drugs in New York City, 2001–2005 and 2011–2015. Drug Alcohol Depend. 2018;185:391–7.

Burnett JC, Broz D, Spiller MW, Wejnert C, Paz-Bailey G. HIV infection and HIV-associated behaviors among persons who inject drugs—20 cities, United States, 2015. Morb Mortal Wkly Rep. 2018;67(1):23.

Meyer JP, Althoff AL, Altice FL. Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis. 2013;57(9):1309–17.

Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.

Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355–66.

Rich KM, Bia J, Altice FL, Feinberg J. Integrated models of care for individuals with opioid use disorder: how do we prevent HIV and HCV? Curr HIV/AIDS Rep. 2018;15(3):266–75.

Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behav. 2003;7(1):61–72.

Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. Aids. 2008;22(11):1247–56.

Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM, Bimirew MA, Kassie DM. Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: a qualitative study from Ethiopia. PLoS One. 2014;9(5):e97353.

Mimiaga MJ, Safren SA, Dvoryak S, Reisner SL, Needle R, Woody G. “We fear the police, and the police fear us”: structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care. 2010;22(11):1305–13.

Weiss L, Netherland J, Egan JE, et al. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56:S68–75.

Fiellin DA, Weiss L, Botsko M, et al. Drug treatment outcomes among HIV-infected opioid dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011;56(0 1). https://doi.org/10.1097/QAI.0b013e3182097537 .

Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.

Egan JE, Netherland J, Gass J, Finkelstein R, Weiss L, collaborative B. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. J Acquir Immune Defic Syndr. 2011;56:S46–53.

Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients’ reasons for choosing office-based buprenorphine: preference for patient-centered care. J Addict Med. 2010;4(4):204.

Tofighi B, Leonard N, Greco P, Acosta MC, Nunes E, Lee JD. Technology use patterns among patients enrolled in inpatient detoxification treatment. J Addict Med. 2019;13:279–86.

Creswell JW, Miller DL. Determining validity in qualitative inquiry. Theory Pract. 2000;39(3):124–30.

Creswell JW, Clark VL. Designing and conducting mixed methods research: Sage publications; 2017.

Committee on Crossing the Quality Chasm, Adaptation to Mental Health, Addictive Disorders. Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series. Washington DC: National Academy Press; 2006.

Idrisov B, Lunze K, Cheng DM, et al. Role of substance use in HIV care cascade outcomes among people who inject drugs in Russia. Addict Sci Clin Pract. 2017;12(1):30.

Downing M, Knight K, Reiss T, et al. Drug users talk about HIV testing: motivating and deterring factors. AIDS Care. 2001;13(5):561–77.

Hutchinson AB, Corbie-Smith G, Thomas SB, Mohanan S, Del Rio C. Understanding the patient's perspective on rapid and routine HIV testing in an inner-city urgent care center. AIDS Educ Prev. 2004;16(2):101–14.

MacPherson P, Lalloo DG, Webb EL, et al. Effect of optional home initiation of HIV care following HIV self-testing on antiretroviral therapy initiation among adults in Malawi: a randomized clinical trial. JAMA. 2014;312(4):372–9.

Bourne C, Knight V, Guy R, Wand H, Lu H, McNulty A. Short message service reminder intervention doubles sexually transmitted infection/HIV re-testing rates among men who have sex with men. Sex Transm Infect. 2011;87(3):229–31.

Campbell CK, Lippman SA, Moss N, Lightfoot M. Strategies to increase HIV testing among MSM: a synthesis of the literature. AIDS Behav. 2018;22:1–26.

Tofighi B, Nicholson JM, McNeely J, Muench F, Lee JD. Mobile phone messaging for illicit drug and alcohol dependence: a systematic review of the literature. Drug Alcohol Rev. 2017;36(4):477–91.

Simeone C, Shapiro B, Lum PJ. Integrated HIV care is associated with improved engagement in treatment in an urban methadone clinic. Addict Sci Clin Pract. 2017;12(1):19.

Press KR, Zornberg GZ, Geller G, Carrese J, Fingerhood MI. What patients with addiction disorders need from their primary care physicians: a qualitative study. Subst Abus. 2016;37(2):349–55.

Lam Y, Westergaard R, Kirk G, et al. Provider-level and other health systems factors influencing engagement in HIV care: a qualitative study of a vulnerable population. PLoS One. 2016;11(7):e0158759.

Smith LR, Fisher JD, Cunningham CO, Amico KR. Understanding the behavioral determinants of retention in HIV care: a qualitative evaluation of a situated information, motivation, behavioral skills model of care initiation and maintenance. AIDS Patient Care STDs. 2012;26(6):344–55.

Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.

Sullivan LE, Tetrault J, Bangalore D, Fiellin DA. Training HIV physicians to prescribe buprenorphine for opioid dependence. Subst Abus. 2006;27(3):13–8.

Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med. 2004;19(11):1096–103.

Arora S, Kalishman S, Thornton K, et al. Project ECHO (Project Extension for Community Healthcare Outcomes): a national and global model for continuing professional development. J Contin Educ Health Prof. 2016;36:S48–9.

Sherer R, Stieglitz K, Narra J, et al. HIV multidisciplinary teams work: support services improve access to and retention in HIV primary care. AIDS Care. 2002;14(sup1):31–44.

Schackman BR, Merrill JO, McCarty D, Levi J, Lubinski C. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis. 2006;43(Supplement_4):S247–53.

Hall BJ, Sou K-L, Beanland R, et al. Barriers and facilitators to interventions improving retention in HIV care: a qualitative evidence meta-synthesis. AIDS Behav. 2017;21(6):1755–67.

Pilowsky DJ, Wu L-T, Burchett B, Blazer DG, Ling W. Depressive symptoms, substance use, and HIV-related high-risk behaviors among opioid-dependent individuals: results from the Clinical Trials Network. Subst Use Misuse. 2011;46(14):1716–25.

Tucker JS, Burnam MA, Sherbourne CD, Kung F-Y, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573–80.

Chaudhry AA, Botsko M, Weiss L, et al. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J Acquir Immune Defic Syndr. 2011;56:S14–21.

Risher KA, Kapoor S, Daramola AM, et al. Challenges in the evaluation of interventions to improve engagement along the HIV care continuum in the United States: a systematic review. AIDS Behav. 2017;21(7):2101–23.

Gardner LI, Marks G, Craw JA, et al. A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis. 2012;55(8):1124–34.

Thông tin
Thông tin xuất bản

Harm Reduction Journal

Tập 16 Số 1

Thông tin tác giả